Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: EN Amsterdam
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Pharming Group NV

+ Add to Watchlist


0.3300 EUR 0.0070 2.08%

As of 10:34:59 ET on 05/04/2015.

Snapshot for Pharming Group NV (PHARM)

Open: 0.3380 Day's Range: 0.3250 - 0.3380 Volume: 2,508,629
Previous Close: 0.3370 52wk Range: 0.3040 - 0.6500 1-Yr Rtn: -32.02%

Stock Chart for PHARM

No chart data available.
  • PHARM:NA 0.3280
  • 1D
  • 1M
  • 1Y
Interactive PHARM Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for PHARM

Current P/E Ratio (ttm) 13.2000
Estimated P/E(12/2015) -
Relative P/E vs. AEX 0.4888
Earnings Per Share (EUR) (ttm) 0.0250
Est. EPS (EUR) (12/2015) -0.0100
Est. PEG Ratio -
Market Cap (M EUR) 134.66
Shares Outstanding (M) 408.07
30 Day Average Volume 3,420,727
Price/Book (mrq) 4.5081
Price/Sale (ttm) 6.0939
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for PHARM

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for PHARM

Pharming Group NV is a biopharmaceutical company involved with the development, production and commercialization of human therapeutic proteins to be used in highly innovative therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage, and surgical/traumatic bleeding.

Simon De Vries "Sijmen"CEO/CFOBruno M L GiannettiChief Operating Officer
Pericles Calias "Perry"Chief Scientific Officer
More Company Profile & Key Executives for PHARM

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil